July 25, 2011 -- Immune Response BioPharma, Inc. Reports First Half of 2011 Results Sees REMUNE as the Gold Standard of Treatment for HIV/AIDS Predicts 90% Market Share, Likely Will Build a REMUNE Manufacturing Plant in Virginia and Close to Receiving Funding.
First Half 2011 Highlights
- Initiated our sepsis drug program Sepsicillin which Dr. LaRosa of Brown University has tentatively agreed to lead the Phase 1 clinical testing of our proprietary antibiotic BPI formulation.
- Initiated plans to begin a Phase 2 Dose ranging clinical trial for NeuroVax, multiple CRO’s are ready to handle the 200 plus patient trials.
- Initiated plans to file an NDA for REMUNE & RemuneX formerly IR103 HIV/AIDS Vaccines and notified the FDA of our plans including an open letter to the FDA.
- Incorporated in the state of Delaware in June 2011, and sets $1.00 per share dividend policy.
- Acquired domain properties sepsicillin.com and neurovax.net
- Received support from Governor Bob McDonnell’s office for a REMUNE manufacturing plant to be built in Virginia IRBP thanks Gov. McDonnell.
Guidance for the 2nd Half 2011:
- Capitalize the company. IRBP will not provide financial guidance until the company has been fully capitalized.
- Appoint key board members, fill key executive, and management positions.
- File our patents for our drug discovery pipeline. & move the clinical pipeline forward by filing IND’s for NeuroVax, Sepsicillin, & RAVAX for Rheumatoid Arthritis.
- Initiate NDA filings for REMUNE & RemuneX formerly IR103 upon CGMP’s FDA manufacturing with a third party or building our own plant in Virginia.
“We are proud of the work we have done in such a short period of time. There remains much outstanding work to do. IRBP has a great pipeline and we have multiple goals on shot with our NeuroVax MS Vaccine the technology, with applications of the drug in RA with our drug RAVAX. We believe REMUNE holds the safest and most effective treatment option for HIV/AIDS the HAART drugs are just plain toxic and poisonous, I am committed to saving lives and getting patients the vaccine” Mr. Buswell COO.
“REMUNE is a winner hands down and see the vaccine as the gold standard of treatment, eventually 90% market share , as soon as we have clarity on CGMP’s manufacturing we will press forward on an NDA for REMUNE. I believe we are close to receiving funding and support from a prominent businessman and we will move forward building a dynamic pharmaceutical company to save lives. Those who wait to partner with IRBP and wait to collaborate including big pharma will lose out” Mr. Buswell COO.
